Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03598309 · ClinicalTrials.gov registry record · Phase 2
Phase II Trial to Modulate Intermediate Endpoint Biomarkers in Former and Current Smokers
A Phase 2 study of Lung Diseases and Lung Cancer, Protection Against, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Active
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
- 1
- Study location
NCT03598309: Active Phase 2 study of Lung Diseases and Lung Cancer, Protection Against, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
NCT03598309 is a Phase 2 study of Lung Diseases and Lung Cancer, Protection Against that is active but no longer recruiting, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 19 participants, below the 739-participant average among 31 other Lung Diseases trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03598309, a Phase 2 study of Lung Diseases and Lung Cancer, Protection Against, is active but no longer recruiting, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to find out if an investigational combination drug called Lovaza (made with fish oils)+Curcumin C3 Complex (made from a root called curcumin) can help reduce the size of lung nodules. Researchers also want to find out if the combination of Lovaza+Curcumin C3 Complex is safe and tolerable.
Primary Outcome
Difference in the average change in bronchial nodule size from baseline to end of therapy at 6 months for each study arm. A lower size is taken to be the desired value for participants receiving study drug, assuming an increase in size for the placebo arm.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Curcumin C3 complex®
- DRUG Lovaza®
Study Locations (1)
Florida
- H. Lee Moffitt Cancer Center and Research Institute - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2019-06-05 |
| Est. Completion | 2026-05 |
| Phase | Phase 2 |
What the registry record for NCT03598309 still lists
NCT03598309 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 739-participant average among 31 other Lung Diseases trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Lung Diseases appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT03598309 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT03598309 about?
NCT03598309 is a clinical study titled "Phase II Trial to Modulate Intermediate Endpoint Biomarkers in Former and Current Smokers". The purpose of this study is to find out if an investigational combination drug called Lovaza (made with fish oils)+Curcumin C3 Complex (made from a root called curcumin) can help reduce the size of lung nodules. Researchers also want to find out if the combination of Lovaza+Curcumin C3 Complex is s...
What is the current status of trial NCT03598309?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2019-06-05. Estimated completion is 2026-05.
What conditions does trial NCT03598309 study?
This clinical trial studies the following conditions: Lung Diseases, Lung Cancer, Protection Against.
What interventions are being tested in trial NCT03598309?
The interventions under investigation include: Placebo (OTHER), Curcumin C3 complex® (DRUG), Lovaza® (DRUG).
Who is sponsoring clinical trial NCT03598309?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03598309 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03598309's enrollment target sits among peer trials
19 31st of 31 higher than 1 of 31 other Lung Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)
RECRUITING · Phase 2
-
A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
RECRUITING · Phase 2
-
A Study of Mosliciguat in PH-ILD
ACTIVE NOT RECRUITING · Phase 2
-
A Study To Investigate The Safety, Toleration And Efficacy of PF00610355 In Chronic Obstructive Pulmonary Disease (COPD) Patients.
COMPLETED · Phase 2
-
Real World Registry for Use of the Ion Endoluminal System
RECRUITING
-
American Lung Association (ALA) Lung Health Cohort
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI